CPRX
Price
$25.87
Change
+$0.51 (+2.01%)
Updated
Jun 6 closing price
Capitalization
3.09B
59 days until earnings call
DNLI
Price
$14.70
Change
+$0.48 (+3.38%)
Updated
Jun 6 closing price
Capitalization
2.07B
53 days until earnings call
Interact to see
Advertisement

CPRX vs DNLI

Header iconCPRX vs DNLI Comparison
Open Charts CPRX vs DNLIBanner chart's image
Catalyst Pharmaceuticals
Price$25.87
Change+$0.51 (+2.01%)
Volume$1.2M
Capitalization3.09B
Denali Therapeutics
Price$14.70
Change+$0.48 (+3.38%)
Volume$1.79M
Capitalization2.07B
CPRX vs DNLI Comparison Chart
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPRX vs. DNLI commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a StrongBuy and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (CPRX: $24.54 vs. DNLI: $13.04)
Brand notoriety: CPRX and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 59% vs. DNLI: 82%
Market capitalization -- CPRX: $3.09B vs. DNLI: $2.07B
CPRX [@Biotechnology] is valued at $3.09B. DNLI’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 2 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CPRX’s FA Score: 2 green, 3 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CPRX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 3 bullish TA indicator(s).

  • CPRX’s TA Score: 6 bullish, 3 bearish.
  • DNLI’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than DNLI.

Price Growth

CPRX (@Biotechnology) experienced а +0.90% price change this week, while DNLI (@Biotechnology) price change was -4.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

CPRX is expected to report earnings on Aug 06, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($3.09B) has a higher market cap than DNLI($2.07B). CPRX YTD gains are higher at: 17.585 vs. DNLI (-36.016). CPRX has higher annual earnings (EBITDA): 233M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. CPRX (518M). CPRX has less debt than DNLI: CPRX (3.19M) vs DNLI (48.7M). CPRX has higher revenues than DNLI: CPRX (492M) vs DNLI (0).
CPRXDNLICPRX / DNLI
Capitalization3.09B2.07B150%
EBITDA233M-492.89M-47%
Gain YTD17.585-36.016-49%
P/E Ratio16.15N/A-
Revenue492M0-
Total Cash518M832M62%
Total Debt3.19M48.7M7%
FUNDAMENTALS RATINGS
CPRX vs DNLI: Fundamental Ratings
CPRX
DNLI
OUTLOOK RATING
1..100
1365
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
17100
SMR RATING
1..100
3395
PRICE GROWTH RATING
1..100
4190
P/E GROWTH RATING
1..100
9398
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (62) in the Pharmaceuticals Other industry is in the same range as DNLI (93) in the Biotechnology industry. This means that CPRX’s stock grew similarly to DNLI’s over the last 12 months.

CPRX's Profit vs Risk Rating (17) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that CPRX’s stock grew significantly faster than DNLI’s over the last 12 months.

CPRX's SMR Rating (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (95) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

CPRX's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (90) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

CPRX's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as DNLI (98) in the Biotechnology industry. This means that CPRX’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXDNLI
RSI
ODDS (%)
N/A
Bearish Trend 12 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
79%
Bullish Trend 12 days ago
75%
Momentum
ODDS (%)
Bullish Trend 12 days ago
78%
Bearish Trend 12 days ago
81%
MACD
ODDS (%)
Bullish Trend 12 days ago
74%
Bearish Trend 12 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
70%
Bearish Trend 12 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
80%
Bearish Trend 12 days ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 20 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
69%
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
70%
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-1.21%
VIR - CPRX
44%
Loosely correlated
+2.15%
CRNX - CPRX
44%
Loosely correlated
+1.39%
SANA - CPRX
43%
Loosely correlated
+12.50%
DNLI - CPRX
42%
Loosely correlated
-1.29%
FOLD - CPRX
41%
Loosely correlated
-2.24%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.29%
BEAM - DNLI
61%
Loosely correlated
-0.88%
RCKT - DNLI
59%
Loosely correlated
+6.44%
NTLA - DNLI
59%
Loosely correlated
+3.59%
ARWR - DNLI
58%
Loosely correlated
+1.24%
RGNX - DNLI
58%
Loosely correlated
-5.84%
More